文章核心观点 - 公司开发的抗CD3单克隆抗体foralumab与糖尿病药物semaglutide(商品名Ozempic和Wegovy)联合使用,可以显著降低肥胖小鼠的炎症反应 [1][4] - 公司计划将foralumab与semaglutide联合用于人体临床试验,希望能改善患者使用GLP-1受体激动剂类药物时的不良反应,帮助患者长期坚持用药 [5] - 公司将在明年开始进行上述联合用药的人体临床试验 [6] 公司概况 - 公司CEO Ivor Elrifi此前是一家大型国际律所的专利部门全球主席,对公司的技术有近15年的了解,希望从律师转型到更多参与公司业务发展,特别是帮助患者 [2] - 公司正在开发的主要产品是一种名为foralumab的全人源单克隆抗体,可以结合CD3,目前正在进行多项临床试验,包括治疗继发性进行性多发性硬化症和阿尔茨海默病 [3] 研究结果 - 公司与哈佛医学院附属的布里格姆医院合作,在肥胖小鼠模型上进行了foralumab联合semaglutide的研究,结果显示可以大幅降低炎症反应 [4] - 研究发现,联合用药可以有效抑制导致"细胞因子风暴"的炎症标志物 [5]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has entered into a securities purchase agreement for the purchase and sale of 5,263,158 common shares at a purchase price of $0.95 per share pursuant to a registered direct offering, resulting ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately. "We are delighted to welcome Ivor Elrifi as the new CEO of Tiziana Life Sciences," said Gabriele Cerrone, Fo ...

"We are thrilled to receive Fast Track designation from the FDA for intranasal foralumab for the treatment of Multiple Sclerosis," said Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences. "This designation underscores the potential of foralumab to address critical unmet needs in the treatment of neurodegenerative diseases. We are committed to advancing this promising therapy as quickly as possible to benefit patients." Foralumab, a fully human anti-CD3 monoclonal antibody, is a biol ...

About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The Canberra Times, an ...

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non-dilutive funding of $3.4 million and issued a corporate update video available here. About Foralumab About Tiziana Life Sciences For further inquiries: [1] https://www.pnas.org/doi/10.1073/pnas.2220272120 Gabriele Cerro ...

文章核心观点 - 公司获340万美元非稀释资金支持鼻内福拉珠单抗2期试验及阿尔茨海默病研究，并发布公司更新视频 [1][4] 公司情况 - 公司是临床阶段生物制药公司，用变革性药物递送技术开发突破性疗法，创新鼻腔给药法相比静脉给药在疗效、安全性和耐受性上有提升潜力 [4] - 公司领先候选药物鼻内福拉珠单抗是唯一全人抗CD3单克隆抗体，在既往研究中展现出良好安全性和临床反应，其免疫疗法替代途径技术已获专利且有多项申请待批，有望实现广泛管线应用 [4] 资金用途 - 340万美元非稀释资金用于支持鼻内福拉珠单抗在非活动性继发进展型多发性硬化症的2期试验及阿尔茨海默病研究，公司还将在短期内探索获取更多非稀释资金的途径 [4] 药物情况 - 福拉珠单抗能结合T细胞受体，通过调节T细胞功能抑制炎症，在COVID、多发性硬化症患者及健康受试者中均有此效果 [4] - 非活动性继发进展型多发性硬化症鼻内福拉珠单抗2期试验于2023年11月开始筛选患者，鼻用抗CD3单克隆抗体免疫调节是治疗神经炎症和神经退行性人类疾病的新途径 [4]